PTX Media related, page-142

(This post is intended to provide more clarity and detail than my previous post concerning Delveinsight’s market research report on CAR-T markets. I requested that post be removed after another poster took offence at my wording. However, I am keen that my key message not be lost - if you are tempted to hand over thousands of dollars for any “global market research report“ found online, do your due diligence first! )

A word of warning – the internet is awash with "expert" market research reports on every market imaginable. Invariably, these reports cost thousands of dollars. Delveinsight is happy to provide you with research into any cancer market of interest - peripheral T-cell lymphomas (from $2500), AML (from $6950), HER2 –ve breast cancer (from $6950), GBM (from $6950)…….

In fact, Delveinsight’s “Report Store” claims to provide “unparalleled coverage” of not only every cancer market but 5099 different pharmaceutical markets in total, predominantly global. It also offers numerous other services, including advisory services and licensing services which it suggests will help small biotechs land licensing deals with Big Pharma.

A key question to consider here is, who exactly is Delveinsight? What are the credentials of this company? What evidence is there to support the claims of a multinational presence, knowledge of competitive landscaping worldwide and deep expertise in pharma/biotech globally?

The company’s CEO says that the company has served more than 700 clients across 15 geographies in a span of 5 years.

Achieving this acme has been possible due to our clear focus on getting the best talent in the company. We are client-focused market research and consulting firm, and our unwavering focus and commitment towards excellence lead us to proffer best-suited solutions to our clients.

A check of Delveinsight’s website and social media pages (here and here) reveals what seems to be an exclusively Indian organisation - CEO, advisors, specialists and staff - which is at odds with the firm’s claims of both deep and broad global pharma insight and networks.

There are two addresses listed on the company’s website:
USA: 304 S. Jones Blvd #2432, Las Vegas NV 89107
India: Sector-7, Dwarka, New Delhi-110077, India

Google Maps and Google Earth show the following images for these addresses.





I would not pay $3000 for Delveinsight’s CAR-T Pipeline Report, nor would I have confidence in the accuracy of the content of the report.

As suggested here and here, I am not alone in that view and DelveInsight is not alone in being a questionable source of market research on thousands of global pharma markets.

As Prescient establishes a foothold in multiple cancer markets, you may decide to research those markets. If you happen to find online a “market research report” that offers to sell you information about the size of that cancer market, or on the key players in that market, you would be well advised to first research the company behind the report.

Of course, this applies not only to “market research” related to Prescient, but to any other companies in which you may be invested.